App-Quantinova.ai

Assessing tumor response using CT density-volume trajectory in metastatic bladder cancer.

Les Folio - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).

Karen L. Reckamp - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cabozantinib

A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Childrens Oncology Group phase I consortium trial.

Meredith K. Chuk - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cabozantinib

A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).

Sara M. Tolaney - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cabozantinib

The dynamics of biomarkers and bone imaging associated with oral cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).

Ulka N. Vaishampayan - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).

Lipika Goyal - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cabozantinib

Assessment of treatment response using Computed Tomography (CT) tumor volume measurements and lesion number in metastatic urothelial carcinoma (mUC) patients (pts) receiving cabozantinib.

Kimaada Allette - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Cabozantinib

Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo).

Andrea Borghese Apolo - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Cabozantinib

Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.

Youjin Je - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Cabozantinib

A Phase II study of MRI based functional imaging of bone metastases in men with metastatic castrate resistant prostate cancer (mCRPC) receiving XL184.

Alexa Campanile - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Fatima Karzai - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.

Christopher Sweeney - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma.

Sayaka Ikeda - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leiomyosarcoma

Cabozantinib

Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.

Martin Schlumberger - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Medullary thyroid carcinoma

Cabozantinib

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

Karen L. Reckamp - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cabozantinib

Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).

Joel W. Neal - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cabozantinib

Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.

Alexander E. Drilon - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cabozantinib

Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping.

Paul K. Paik - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cabozantinib

Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201.

Jason John Luke - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ocular melanoma

Cabozantinib

TAS-115, a potent MET/VEGFRs-targeted kinase inhibitor with high tolerability, to suppress NSCLC-driven bone disruption.

Hidenori Fujita - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cabozantinib

Filters

366 Abstracts